BioMedNewsBreaks Archive - Page 196 of 224

MondayDec 28, 2020 10:08 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures $12M in Registered Direct Offering

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has announced the closing of its registered direct offering of 3,116,884 shares of its common stock with a single health care-dedicated institutional investor. Genprex secured gross proceeds of $12 million, before deducting commissions and estimated expenses, with the offering priced at-the-market under Nasdaq rules at a price of $3.85 per share. “We believe that the closing of this transaction with a single, health care-dedicated institutional investor is further evidence that the potential of our gene therapies for cancer and diabetes is gaining recognition within the community…

MondayDec 28, 2020 9:38 am

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Featured in Equity Research Report

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in an equity research report by Maxim Group LLC. The piece discusses VistaGen’s strongest positioning yet, based on its pharmaceutical pipeline coupled with financing and a rising mental health pace. The report reads, “On 12/18, VistaGen announced pricing of an equity financing, raising gross proceeds of $100M (~$93M net) and bringing the company's cash balance to ~$103M. Importantly, the financing included participation of some leading institutional health care investors, which in our view is further validation of VistaGen's…

WednesdayDec 23, 2020 2:44 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Integrates Data, AI to Pave Path for Better Health Outcomes

Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery, is positioned to play a critical role in the precision oncology industry. The company integrates AI technology with oncologists’ clinical decision-making processes, paving the way for improved health outcomes. A recent article discussing this reads, “POAI is focused on the use of data and artificial intelligence to develop personalized cancer therapies through its trove of valuable assets, including a database of clinically validated historical and outcome data from patient tumors, an in-house Clinical Laboratory Improvement Amendments (‘CLIA’)-certified…

WednesdayDec 23, 2020 10:36 am

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Closes $100M Underwritten Public Offering

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, has announced the closing of its $100 million underwritten public offering. The offering consisted of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share, and 2,000,000 shares of its Series D convertible preferred stock at a public offering price of $21.16 per share. All of the securities in the offering were sold by VistaGen. Acuta Capital, New Enterprise Associates (“NEA”), OrbiMed and Venrock Healthcare Capital Partners, among others, participated in…

WednesdayDec 23, 2020 10:20 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters into Estimated $12-Million Securities Purchase Agreement

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor. The agreement outlines the purchase and sale of 3,116,884 shares of Genprex common stock; the purchase price of those shares will be $3.85 per share in a registered direct offering priced at-the-market under Nasdaq rules. The agreement, which is expected to close on or before Dec. 24, 2020, also stipulates that no warrants will be issued in connection with the transaction. The offering closing is subject to the…

WednesdayDec 23, 2020 9:00 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Pricing of $10M Public Offering

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced the pricing of an underwritten public offering of 5,000,000 shares of common stock and warrants to purchase up to 2,500,000 shares of common stock. According to the update, the shares of common stock and warrants are being sold together at a combined public offering price of $2.00 per share and warrant. The warrants will have an exercise price of $2.20 per share and will be immediately exercisable and expire five years from…

TuesdayDec 22, 2020 2:55 pm

BioMedNewsBreaks – Why RYAH Group Inc. Is ‘One to Watch’

RYAH Group is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. Through its IoT dose-measuring devices and AI analytics, RYAH is focused on expanding understanding of the value of devices combined with data to positively impact the future treatment of patients for various medical conditions. A recent article discussing the company reads, “Since it began developing and commercializing its smart inhaler solution in 2018, the company has evolved a complete IoT device and data analytics platform that includes multiple delivery mechanisms, designed…

TuesdayDec 22, 2020 2:41 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Takes Game-Changing Visualization Method to the Next Level

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is at the forefront of change in its focus to establish a new standard of care in visualizing cancer. Minimally invasive surgery (“MIS”) using white light to illuminate tumor growth is the current standard of care for bladder cancer. This method is highly effective for visualizing cancerous tumors that protrude above the bladder’s wall. However, due to the difficulty in distinguishing flat tumors from normal tissue, it is nearly impossible to visualize the margins of the tumor under current standards. Game-changing to the industry has been the introduction of blue…

TuesdayDec 22, 2020 2:28 pm

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Aims to Identify Best Delivery Method for Lead Drug Candidate

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, recently submitted a protocol amendment request to the U.S. Food and Drug Administration (“FDA”). Approval of the amendment will allow AzurRx to modify its current Phase 2b OPTION 2 trial of MS1819 in cystic fibrosis (“CF”) patients to add a study arm that uses immediate release capsules (https://ibn.fm/SxH8F). The existing study arm uses delayed release capsules, so the expansion will allow AzurRx to compare data from both arms to determine the best delivery method for its lead product, an exocrine pancreatic…

TuesdayDec 22, 2020 1:21 pm

BioMedNewsBreaks – TPT Global Tech Inc. (TPTW) Announces Launch of ‘QuikLAB’ and ‘QuikPASS’ Apps

TPT Global Tech (OTC: TPTW), a provider of telecommunications, medical technology, media content for domestic and international syndication as well as technology solutions, today announced the release of two new products and services for use at its TPT Med Tech division. These include its "QuikLAB" App, designed for use in monitoring patient testing and vaccination history, and its "QuikPASS" Mobile App. QuikPASS is designed to allow entrance to any facility or country based on patient test and vaccination results on a real-time basis worldwide. The QuikPASS App will be offered free of charge to U.S. and international consumer markets. TPT…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures $12M in Registered Direct Offering

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Featured in Equity Research Report

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Integrates Data, AI to Pave Path for Better Health Outcomes

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Closes $100M Underwritten Public Offering

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters into Estimated $12-Million Securities Purchase Agreement

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Pricing of $10M Public Offering

BioMedNewsBreaks – Why RYAH Group Inc. Is ‘One to Watch’

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Takes Game-Changing Visualization Method to the Next Level

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Aims to Identify Best Delivery Method for Lead Drug Candidate

BioMedNewsBreaks – TPT Global Tech Inc. (TPTW) Announces Launch of ‘QuikLAB’ and ‘QuikPASS’ Apps

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search